This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(14), 2292-8
Citation
Sosman, Jeffrey A; Carrillo, Carole; Urba, Walter J; Flaherty, Lawrence; Atkins, Michael B; Clark, Joseph I; Dutcher, Janet; Margolin, Kim A; Mier, James; Gollob, Jarod; Kirkwood, John M; Panka, David J; Crosby, Nancy A; O'Boyle, Kevin; LaFleur, Bonnie; Ernstoff, Marc S. (2008). Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(14), 2292-8. https://doi.org/10.1200/JCO.2007.13.3165